These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 8801513

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD, Crook JM, Lukka H.
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Strontium 89 therapy for the palliation of pain due to osseous metastases.
    Robinson RG, Preston DF, Schiefelbein M, Baxter KG.
    JAMA; 1995 Aug 02; 274(5):420-4. PubMed ID: 7542352
    [Abstract] [Full Text] [Related]

  • 5. Clinical experience with strontium-89 in prostatic and breast cancer patients.
    Robinson RG, Preston DF, Baxter KG, Dusing RW, Spicer JA.
    Semin Oncol; 1993 Jun 02; 20(3 Suppl 2):44-8. PubMed ID: 8503027
    [Abstract] [Full Text] [Related]

  • 6. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB, Yan WL, Dai JC, Xu F, Yuan Q, Shi HH.
    Zhonghua Nan Ke Xue; 2008 Sep 02; 14(9):819-22. PubMed ID: 18998467
    [Abstract] [Full Text] [Related]

  • 7. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, Maini CL.
    J Nucl Med; 2002 Jan 02; 43(1):79-86. PubMed ID: 11801708
    [Abstract] [Full Text] [Related]

  • 8. Palliation of bone pain in patients with metastatic cancer using strontium-89 (Metastron).
    Kan MK.
    Cancer Nurs; 1995 Aug 02; 18(4):286-91. PubMed ID: 7545083
    [Abstract] [Full Text] [Related]

  • 9. The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89.
    De Ruysscher D, Spaas P, Specenier P.
    Acta Urol Belg; 1996 Sep 02; 64(3):13-9. PubMed ID: 8946776
    [Abstract] [Full Text] [Related]

  • 10. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
    Papatheofanis FJ.
    J Nucl Med; 2000 Jun 02; 41(6):1021-4. PubMed ID: 10855628
    [Abstract] [Full Text] [Related]

  • 11. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.
    Porter AT, McEwan AJ.
    Semin Oncol; 1993 Jun 02; 20(3 Suppl 2):38-43. PubMed ID: 7684865
    [Abstract] [Full Text] [Related]

  • 12. Question of the month--January 1995. What is the optimal dose of 89Sr for bone pain palliation?
    Khader Z.
    Nucl Med Commun; 1995 Apr 02; 16(4):306. PubMed ID: 7542759
    [No Abstract] [Full Text] [Related]

  • 13. [Possibilities of systemic radiotherapy with high-purity 89Sr chloride in the treatment of bone metastases].
    Fomin DK, Tararukhina OB, Nazarov AA.
    Vestn Rentgenol Radiol; 2012 Apr 02; (2):29-31. PubMed ID: 22730757
    [Abstract] [Full Text] [Related]

  • 14. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N.
    J Nucl Med; 1999 Feb 02; 40(2):256-61. PubMed ID: 10025832
    [Abstract] [Full Text] [Related]

  • 15. Systemic radionuclide therapy of bone metastases with strontium-89.
    Porter AT, Davis LP.
    Oncology (Williston Park); 1994 Feb 02; 8(2):93-6; discussion 96, 99-101. PubMed ID: 8167090
    [Abstract] [Full Text] [Related]

  • 16. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
    Malmberg I, Persson U, Ask A, Tennvall J, Abrahamsson PA.
    Urology; 1997 Nov 02; 50(5):747-53. PubMed ID: 9372886
    [Abstract] [Full Text] [Related]

  • 17. [Effectiveness of repeated systematic radiotherapy for generalized prostate cancer].
    Kiselev EN, Korytova LI, Karelin MI.
    Vopr Onkol; 2005 Nov 02; 51(6):689-91. PubMed ID: 17037036
    [Abstract] [Full Text] [Related]

  • 18. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
    Haesner M, Buchali K, Pink V, Lips H.
    Nuklearmedizin; 1992 Mar 02; 31(2):48-52. PubMed ID: 1373485
    [Abstract] [Full Text] [Related]

  • 19. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M.
    Bone; 2006 Jul 02; 39(1):35-41. PubMed ID: 16434248
    [Abstract] [Full Text] [Related]

  • 20. Strontium-89 therapy for painful osseous metastatic prostate and breast cancer.
    Hansen DV, Holmes ER, Catton G, Thorne DA, Chadwick DH, Schmutz DA.
    Am Fam Physician; 1993 Jun 02; 47(8):1795-800. PubMed ID: 7684554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.